BioScale, a maker of protein measurement technology, disclosed in SEC filings that it has raised $5.2 million in convertible debt. 37 separate investors participated in the offering.

BioScale was founded in 2002 by CEO Mark Lundstrom and three interdisciplinary MIT professors. Since then the Company has assembled development, engineering, manufacturing and an industry-seasoned commercial team to globally launch its AMMP assay technology and ViBE platform into the pharmaceutical, biotech, life science, and bioprocess markets. We are also pursuing partnering for diagnostic and specialty applications. The company's new 30,000 sq. ft. global headquarters and manufacturing site are located in Lexington, Massachusetts.